---
title: "Genrix Bio: GR1802 injection for adolescent seasonal allergic rhinitis indication has received clinical trial approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253601655.md"
description: "Genrix Bio recently announced that its GR1802 injection for the clinical trial application targeting seasonal allergic rhinitis in adolescents has been approved by the National Medical Products Administration. This product is a recombinant fully human anti-IL-4Rα monoclonal antibody independently developed by the company, which has obtained clinical trial approvals for multiple indications, including adult atopic dermatitis, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, and allergic rhinitis, with some indications having entered the Phase III clinical trial stage"
datetime: "2025-08-19T09:38:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253601655.md)
  - [en](https://longbridge.com/en/news/253601655.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253601655.md)
generator: "portal-rs"
---

# Genrix Bio: GR1802 injection for adolescent seasonal allergic rhinitis indication has received clinical trial approval

Genrix Bio announced that the company recently received the "Notice of Approval for Clinical Trials of Drugs" issued by the National Medical Products Administration. The clinical trial application for the indication of adolescent seasonal allergic rhinitis for its research product GR1802 injection has been approved. GR1802 injection is a recombinant fully human anti-IL-4Rα monoclonal antibody independently developed by the company, targeting IL-4Rα. Previously, GR1802 injection had obtained clinical trial approval notices for multiple indications, with adult moderate to severe atopic dermatitis, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, and allergic rhinitis indications in the Phase III clinical trial stage, and asthma indication in the Phase II clinical trial stage, while the indication for pediatric/adolescent atopic dermatitis is in the Ib/II clinical trial stage

### Related Stocks

- [688443.CN](https://longbridge.com/en/quote/688443.CN.md)

## Related News & Research

- [Iman Gadzhi Acquires Stake in €45 Million AI-Powered Cold Email Platform ListKit](https://longbridge.com/en/news/296750846.md)
- [04:03 ETDizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026](https://longbridge.com/en/news/296585269.md)
- [Vector Science files US provisional patent for orthopedic tissue-regeneration peptide platform](https://longbridge.com/en/news/296483037.md)
- [Navigator invests about EUR 115 million in new tissue paper machine at Aveiro complex](https://longbridge.com/en/news/296775961.md)
- [REG - Ridgeview Partners Pinewood Tech Gp PLC - Update on Letter of Intent](https://longbridge.com/en/news/296635822.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**